Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5696805 | Reproductive BioMedicine Online | 2017 | 6 Pages |
Abstract
Triptorelin 0.2âmg and leuprolide 1âmg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 were recruited. Patients with high serum oestradiol levels on HCG day (>3000âpg/ml) indicating a risk of OHSS consisted of the study groups (A and B). Patients with serum oestradiol levels less than 3000âpg/ml consisted of the control group (C). A single injection of 0.2âmg triptorelin, 1âmg leuprolide and 10000âIU HCG were administered for final oocyte triggering in groups A (n = 63), B (n = 74) and C (n = 131), respectively. Demographic parameters were comparable between the groups. No cases of severe or moderate OHSS occurred in any group. The clinical pregnancy rates were 31.7%, 37.8% and 32.8% in groups A, B and C, respectively. Both injections had comparable efficacy in clinical outcome and OHSS risk. Regardless of preferred drug, GnRH agonist trigger for final oocyte maturation seems to be safe for patients with high OHSS risk, and can be safely used in fresh embryo transfer cycles.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Yavuz Emre Åükür, Batuhan Ãzmen, Elif Didem Ãzdemir, Mehmet Murat Seval, Erkan Kalafat, Murat Sönmezer, Bülent Berker, RuÅen Aytaç, Cem Somer AtabekoÄlu,